These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22522266)

  • 1. Detecting and treating prostate cancer: a surgeon's perspective.
    Buchan NC
    N Z Med J; 2012 Apr; 125(1353):6-8. PubMed ID: 22522266
    [No Abstract]   [Full Text] [Related]  

  • 2. Revised status of PSA testing in the early detection and treatment of prostate cancer.
    Lamb DS; Delahunt B; Nacey JN
    N Z Med J; 2011 Nov; 124(1345):13-5. PubMed ID: 22072161
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 5. Active surveillance for prostate cancer: has the time finally come?
    Aragon-Ching JB
    J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
    [No Abstract]   [Full Text] [Related]  

  • 6. Precursor isoform of prostate-specific antigen and human kallikrein 2: two new promising biomarkers for the unsolved challenge of early prostate cancer detection.
    Ficarra V; Novara G; Galfano A
    Eur Urol; 2009 Mar; 55(3):556-9. PubMed ID: 19111385
    [No Abstract]   [Full Text] [Related]  

  • 7. The new PSA report: understand the controversy.
    Harv Mens Health Watch; 2012 Feb; 16(7):1-4. PubMed ID: 22474703
    [No Abstract]   [Full Text] [Related]  

  • 8. Perspective on...the new PSA screening recommendations.
    Marsland T; Arena F; Yeilding A; Glodé M; Ellis L; Yu J; Henderson C; Wagman L; Piver S; Minsky B; Rosen S; Poplack D; Potters L; Crawford D; Hoskins W
    Oncology (Williston Park); 2011 Nov; 25(12):1183, 1187-8, 1190. PubMed ID: 22229211
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
    Carroll PR; Whitson JM; Cooperberg MR
    J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
    ;
    Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen dynamics and prostate cancer diagnosis.
    Bartoletti R
    Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer screening: what we know, don't know, and believe.
    Brawley OW
    Ann Intern Med; 2012 Jul; 157(2):135-6. PubMed ID: 22801675
    [No Abstract]   [Full Text] [Related]  

  • 13. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 16. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

  • 17. [The follow-up of PSA tests for the early detection of prostate cancer. The responsibility of the physician to explain treatment methods which are not covered by public health insurance plans].
    Cramer R; Dahm FJ
    Urologe A; 2005 Jul; 44(7):798-800. PubMed ID: 15891867
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate-specific antigen testing for the early detection of prostate cancer.
    Kirby R; Fitzpatrick J
    BJU Int; 2004 Nov; 94(7):966-7. PubMed ID: 15541108
    [No Abstract]   [Full Text] [Related]  

  • 19. Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit".
    Chen CP; Staggers FE; Roach M
    Oncology (Williston Park); 2011 May; 25(6):466, 468. PubMed ID: 21717899
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.